Platelet activating factor levels and metabolism in tangier disease: a case study

被引:4
|
作者
Kolovou, Vana [1 ,2 ,3 ]
Papakonstantinou, Vasiliki D. [3 ]
Stamatakis, George [3 ]
Verouti, Sophia N. [3 ]
Xanthopoulou, Marianna N. [4 ]
Kolovou, Genovefa [1 ,2 ]
Demopoulos, Constantinos A. [3 ]
机构
[1] Onassis Cardiac Surg Ctr, Dept Cardiol, Athens, Greece
[2] Onassis Cardiac Surg Ctr, Mol Immunol Lab, Athens, Greece
[3] Univ Athens, Fac Chem, Biochem Lab, Athens 11528, Greece
[4] Harokopio Univ, Dept Sci Nutr Dietet, Athens, Greece
关键词
PAF; Tangier Disease; Atherosclerosis; Lp-PLA(2); PAF-AH; Lyso-PAF-AT; PAF-CPT; ACETYLHYDROLASE PAF-AH; CASSETTE TRANSPORTER 1; DENSITY-LIPOPROTEIN; PHOSPHOLIPASE A(2); PLASMA; BINDING; CHOLESTEROL; BLOOD; VIVO; LEUKOCYTES;
D O I
10.1186/1476-511X-11-89
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal role of Platelet-Activating Factor (PAF) mediator in atheromatosis was found. Plasma lipoproteins are transporters of the PAF acetylhydrolase (PAF-AH) in cells and known as lipoprotein-phospholipase A(2) (Lp-PLA(2)) in plasma and regulators of PAF levels in blood. In addition, PAF can be biosynthesized from the remodeling and the de novo pathways in which Lyso-platelet activating factor-acetyltransferase (Lyso-PAF-AT) and platelet activating factor-cholinephosphotransferase (PAF-CPT) are the regulatory enzymes. The aim of this study is to investigate in a TD patient with a unique mutation (C2033A), the concentration of PAF in blood, the Equivalent Concentration for 50% aggregation (EC50) values of platelet rich plasma (PRP) toward PAF, adenosine diphosphate (ADP) and thrombin, and the activities of PAF metabolic enzymes Lp-PLA(2), PAF-AH, Lyso-PAF-AT and PAF-CPT. Methods: The EC50 value of PRP was measured by an aggregometer. The determination of the specific activity of PAF-CPT and Lyso-PAF-AT was made after in vitro enzymatic assay, chromatographic separation and measurement of the produced PAF in a biological assay with washed rabbit platelets. The determination of PAF-AH and Lp-PLA(2) was made after an in vitro enzymatic assay from the decay of radioactive PAF. Results: The TD patient had lower bound-PAF values in blood, decreased specific activity of PAF-CPT and Lyso-PAF-AT, increased specific activity of PAF-AH in platelets and leukocytes and Lp-PLA(2) activity in plasma compared to healthy women. The EC50 of PAF and Thrombin were higher compared to healthy women. Conclusion: The increased Lp-PLA(2) activity, as well as, the decreased activities of PAF-CPT and Lyso-PAF-AT, explain the decreased bound-PAF level in TD patient and the EC50 of PAF. However, total PAF is in a normal range and this probably can explain one of the reasons this TD patient has no CAD.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] THE ROLE OF TRANSACYLASES IN THE METABOLISM OF ARACHIDONATE AND PLATELET-ACTIVATING-FACTOR
    SNYDER, F
    LEE, TC
    BLANK, ML
    PROGRESS IN LIPID RESEARCH, 1992, 31 (01) : 65 - 86
  • [22] Metabolism of platelet-activating factor in rat epididymal spermatozoa
    Muguruma, K
    Johnston, JM
    BIOLOGY OF REPRODUCTION, 1997, 56 (02) : 529 - 536
  • [23] METABOLISM OF PLATELET-ACTIVATING-FACTOR IN ULCERATIVE-COLITIS
    THYSSEN, EP
    STENSON, WF
    GASTROENTEROLOGY, 1993, 104 (04) : A789 - A789
  • [24] METABOLISM OF PLATELET-ACTIVATING-FACTOR IN HUMAN-BLOOD
    CARTER, ME
    PRESCOTT, SM
    MCINTYRE, TM
    ZIMMERMAN, GA
    CLINICAL RESEARCH, 1986, 34 (01): : A38 - A38
  • [25] PLASMA PLATELET-ACTIVATING FACTOR LEVELS AND THE RISK OF OSTEOPOROTIC FRACTURES: THE CEOR STUDY
    Ardawi, M. S. M.
    Rouzi, A. A.
    Al-Sibiani, S. A.
    Senani, N. S.
    Qari, M. H.
    Ardawi, J. M. S.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S212 - S212
  • [26] Elevated Levels of Platelet Activating Factor and Its Acetylhydrolase Indicate High Risk of Kawasaki Disease
    Yi, Lunyu
    Zhang, Jing
    Zhong, Jiarong
    Zheng, Yuqiang
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2020, 40 (03): : 159 - 167
  • [27] Platelet activating factor, histamine and tryptase levels in human anaphylaxis
    Vadas, P.
    Perelman, B.
    Liss, G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S148 - S148
  • [28] Platelet-activating factor acetylhydrolases in health and disease
    Tjoelker, LW
    Stafforini, DM
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1488 (1-2): : 102 - 123
  • [29] PLATELET-ACTIVATING FACTOR AS A MEDIATOR OF ALLERGIC DISEASE
    BARNES, PJ
    CHUNG, KF
    PAGE, CP
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1988, 81 (05) : 919 - 934
  • [30] PLATELET-ACTIVATING FACTOR BINDING AND METABOLISM DURING HUMAN-PLATELET AGGREGATION
    VALONE, FH
    THROMBOSIS RESEARCH, 1988, 50 (01) : 103 - 112